Literature DB >> 23386199

Sculpting MHC class II-restricted self and non-self peptidome by the class I Ag-processing machinery and its impact on Th-cell responses.

Charles T Spencer1, Srdjan M Dragovic, Stephanie B Conant, Jennifer J Gray, Mu Zheng, Parimal Samir, Xinnan Niu, Magdalini Moutaftsi, Luc Van Kaer, Alessandro Sette, Andrew J Link, Sebastian Joyce.   

Abstract

It is generally assumed that the MHC class I antigen (Ag)-processing (CAP) machinery - which supplies peptides for presentation by class I molecules - plays no role in class II-restricted presentation of cytoplasmic Ags. In striking contrast to this assumption, we previously reported that proteasome inhibition, TAP deficiency or ERAAP deficiency led to dramatically altered T helper (Th)-cell responses to allograft (HY) and microbial (Listeria monocytogenes) Ags. Herein, we tested whether altered Ag processing and presentation, altered CD4(+) T-cell repertoire, or both underlay the above finding. We found that TAP deficiency and ERAAP deficiency dramatically altered the quality of class II-associated self peptides suggesting that the CAP machinery impacts class II-restricted Ag processing and presentation. Consistent with altered self peptidomes, the CD4(+) T-cell receptor repertoire of mice deficient in the CAP machinery substantially differed from that of WT animals resulting in altered CD4(+) T-cell Ag recognition patterns. These data suggest that TAP and ERAAP sculpt the class II-restricted peptidome, impacting the CD4(+) T-cell repertoire, and ultimately altering Th-cell responses. Together with our previous findings, these data suggest multiple CAP machinery components sequester or degrade MHC class II-restricted epitopes that would otherwise be capable of eliciting functional Th-cell responses.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23386199      PMCID: PMC3798073          DOI: 10.1002/eji.201243087

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  72 in total

1.  In vivo requirement for Atg5 in antigen presentation by dendritic cells.

Authors:  Heung Kyu Lee; Lisa M Mattei; Benjamin E Steinberg; Philipp Alberts; Yun Hee Lee; Alexander Chervonsky; Noboru Mizushima; Sergio Grinstein; Akiko Iwasaki
Journal:  Immunity       Date:  2010-02-18       Impact factor: 31.745

Review 2.  Mechanisms of MHC class I-restricted antigen processing and cross-presentation.

Authors:  Peter Cresswell; Anne L Ackerman; Alessandra Giodini; David R Peaper; Pamela A Wearsch
Journal:  Immunol Rev       Date:  2005-10       Impact factor: 12.988

3.  Sequence analysis of peptides bound to MHC class II molecules.

Authors:  A Rudensky; P Preston-Hurlburt; S C Hong; A Barlow; C A Janeway
Journal:  Nature       Date:  1991-10-17       Impact factor: 49.962

4.  HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells.

Authors:  S Jacobson; R P Sekaly; C L Jacobson; H F McFarland; E O Long
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

5.  Intracellular assembly and transport of endogenous peptide-MHC class II complexes.

Authors:  A Y Rudensky; M Maric; S Eastman; L Shoemaker; P C DeRoos; J S Blum
Journal:  Immunity       Date:  1994-10       Impact factor: 31.745

6.  Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC.

Authors:  M S Malnati; S Ceman; M Weston; R DeMars; E O Long
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

7.  Human cytomegalovirus disrupts the major histocompatibility complex class I peptide-loading complex and inhibits tapasin gene transcription.

Authors:  Anne Halenius; Sebastian Hauka; Lars Dölken; Jan Stindt; Henrike Reinhard; Constanze Wiek; Helmut Hanenberg; Ulrich H Koszinowski; Frank Momburg; Hartmut Hengel
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

8.  Genetic variants in TAP are associated with high-grade cervical neoplasia.

Authors:  Mark H Einstein; Suzanne Leanza; Lydia G Chiu; Nicolas F Schlecht; Gary L Goldberg; Bettie M Steinberg; Robert D Burk
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

9.  Comparison of peptides bound to spleen and thymus class II.

Authors:  P Marrack; L Ignatowicz; J W Kappler; J Boymel; J H Freed
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

10.  Genetic evidence for a new type of major histocompatibility complex class II combined immunodeficiency characterized by a dyscoordinate regulation of HLA-D alpha and beta chains.

Authors:  J Douhan; I Hauber; M M Eibl; L H Glimcher
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  4 in total

1.  The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity.

Authors:  Cristina C Clement; Aniuska Becerra; Liusong Yin; Valerio Zolla; Liling Huang; Simone Merlin; Antonia Follenzi; Scott A Shaffer; Lawrence J Stern; Laura Santambrogio
Journal:  J Biol Chem       Date:  2016-01-06       Impact factor: 5.157

2.  The Human Leukocyte Antigen (HLA)-B27 Peptidome in Vivo, in Spondyloarthritis-susceptible HLA-B27 Transgenic Rats and the Effect of Erap1 Deletion.

Authors:  Eilon Barnea; Dganit Melamed Kadosh; Yael Haimovich; Nimman Satumtira; Martha L Dorris; Mylinh T Nguyen; Robert E Hammer; Tri M Tran; Robert A Colbert; Joel D Taurog; Arie Admon
Journal:  Mol Cell Proteomics       Date:  2017-02-10       Impact factor: 5.911

Review 3.  The melting pot of the MHC II peptidome.

Authors:  Lawrence J Stern; Laura Santambrogio
Journal:  Curr Opin Immunol       Date:  2016-03-25       Impact factor: 7.486

4.  Endogenous antigen processing drives the primary CD4+ T cell response to influenza.

Authors:  Michael A Miller; Asha Purnima V Ganesan; Nancy Luckashenak; Mark Mendonca; Laurence C Eisenlohr
Journal:  Nat Med       Date:  2015-09-28       Impact factor: 53.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.